| Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease S Tsimikas, ES Brilakis, ER Miller, JP McConnell, RJ Lennon, ... New England Journal of Medicine 353 (1), 46-57, 2005 | 998 | 2005 |
| Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American … JE Tamis-Holland, H Jneid, HR Reynolds, S Agewall, ES Brilakis, ... Circulation 139 (18), e891-e908, 2019 | 862 | 2019 |
| A percutaneous treatment algorithm for crossing coronary chronic total occlusions ES Brilakis, JA Grantham, S Rinfret, RM Wyman, MN Burke, ... JACC: Cardiovascular Interventions 5 (4), 367-379, 2012 | 717 | 2012 |
| Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for … ID Moussa, LW Klein, B Shah, R Mehran, MJ Mack, ES Brilakis, JP Reilly, ... Journal of the American college of cardiology 62 (17), 1563-1570, 2013 | 715 | 2013 |
| Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. A Thompson, P Gao, L Orfei, S Watson, E Di Angelantonio, S Kaptoge, ... Lancet (London, England) 375 (9725), 1536-1544, 2010 | 582 | 2010 |
| Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry) ES Brilakis, S Banerjee, D Karmpaliotis, WL Lombardi, TT Tsai, KA Shunk, ... JACC: Cardiovascular Interventions 8 (2), 245-253, 2015 | 542 | 2015 |
| Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized … S Garcia, Y Sandoval, H Roukoz, S Adabag, M Canoniero, ... Journal of the American College of Cardiology 62 (16), 1421-1431, 2013 | 480 | 2013 |
| Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 … VG Patel, KM Brayton, A Tamayo, O Mogabgab, TT Michael, N Lo, ... JACC: Cardiovascular Interventions 6 (2), 128-136, 2013 | 451 | 2013 |
| Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ... The Lancet 391 (10117), 205-218, 2018 | 421 | 2018 |
| Guiding principles for chronic total occlusion percutaneous coronary intervention: a global expert consensus document ES Brilakis, K Mashayekhi, E Tsuchikane, N Abi Rafeh, K Alaswad, ... Circulation 140 (5), 420-433, 2019 | 388 | 2019 |
| Development and validation of a novel scoring system for predicting technical success of chronic total occlusion percutaneous coronary interventions: the PROGRESS CTO … G Christopoulos, DE Kandzari, RW Yeh, FA Jaffer, D Karmpaliotis, ... JACC: Cardiovascular Interventions 9 (1), 1-9, 2016 | 385 | 2016 |
| Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry DJ Kumbhani, PG Steg, CP Cannon, KA Eagle, SC Smith Jr, S Goto, ... European heart journal 35 (41), 2864-2872, 2014 | 371 | 2014 |
| Plasma leptin and prognosis in patients with established coronary atherosclerosis R Wolk, P Berger, RJ Lennon, ES Brilakis, BD Johnson, VK Somers Journal of the American College of Cardiology 44 (9), 1819-1824, 2004 | 362 | 2004 |
| Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial PJ Devereaux, E Duceppe, G Guyatt, V Tandon, R Rodseth, BM Biccard, ... The Lancet 391 (10137), 2325-2334, 2018 | 336 | 2018 |
| Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up ES Brilakis, JP McConnell, RJ Lennon, AA Elesber, JG Meyer, PB Berger European heart journal 26 (2), 137-144, 2005 | 329 | 2005 |
| Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events S Tsimikas, ES Brilakis, RJ Lennon, ER Miller, JL Witztum, JP McConnell, ... Journal of lipid research 48 (2), 425-433, 2007 | 292 | 2007 |
| Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital OM Jeroudi, ME Alomar, TT Michael, AE Sabbagh, VG Patel, ... Catheterization and Cardiovascular Interventions 84 (4), 637-643, 2014 | 291 | 2014 |
| Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions GE Christakopoulos, G Christopoulos, M Carlino, OM Jeroudi, M Roesle, ... The American journal of cardiology 115 (10), 1367-1375, 2015 | 286 | 2015 |
| Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial JC Tardif, CM Ballantyne, P Barter, JL Dasseux, ZA Fayad, MC Guertin, ... European heart journal 35 (46), 3277-3286, 2014 | 278 | 2014 |
| Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease R Wolk, P Berger, RJ Lennon, ES Brilakis, VK Somers Circulation 108 (18), 2206-2211, 2003 | 276 | 2003 |
Khaldoon AlaswadDirector of the Cardiac Catheterization Laboratory, Henry Ford Hospitalایمیل تأیید شده در hfhs.org
